ECONOMIC IMPACT OF EMICIZUMAB PROPHYLAXIS FOR HEMOPHILIA A WITH AND WITHOUT INHIBITORS

被引：0
|
作者：
Cortesi, P. A. [1 ]
Castaman, G. [2 ]
Mantovani, L. G. [1 ]
机构：
[1] Univ Milano Bicocca, Monza, Italy
[2] Azienda Osped Univ Careggi, Florence, Italy
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PRO53
引用
收藏
页码：S699 / S699
页数：1
相关论文
共 50 条
  • [21] A real-world evidence analysis of the impact of switching from factor VIII to emicizumab prophylaxis in patients with hemophilia A without inhibitors
    Escobar, Miguel
    Bullano, Michael
    Mokdad, Ali G.
    Caicedo, Jorge
    Schultz, Bob G.
    Fan, Qi
    Verma, Sumit
    [J]. EXPERT REVIEW OF HEMATOLOGY, 2023, 16 (06) : 467 - 474
  • [22] Emicizumab use in females with moderate or mild hemophilia A without factor VIII inhibitors who warrant prophylaxis
    Hermans, Cedric
    Ventriglia, Giuliana
    Obaji, Samya
    Beckermann, Benjamin M.
    Lehle, Michaela
    Catalani, Olivier
    d'Oiron, Roseline
    Frenzel, Laurent
    [J]. RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2023, 7 (08)
  • [23] BUDGET IMPACT ANALYSIS OF THE USE OF EMICIZUMAB IN PROPHYLAXIS FOR SEVERE HEMOPHILIA A AND INHIBITORS IN THE PEDIATRIC COPULATION OF THE DOMINICAN REPUBLIC
    Munoz, A.
    Bustamante, A.
    Blanco, J.
    [J]. VALUE IN HEALTH, 2022, 25 (12) : S135 - S136
  • [24] Exposure–Bleeding Count Modeling of Emicizumab for the Prophylaxis of Bleeding in Persons with Hemophilia A with/Without Inhibitors Against Factor VIII
    Fredrik Jonsson
    Christophe Schmitt
    Claire Petry
    Francois Mercier
    Nicolas Frey
    Sylvie Retout
    [J]. Clinical Pharmacokinetics, 2021, 60 : 931 - 941
  • [25] Assessment of the impact of pharmaceutical consultations at initiation of a treatment with emicizumab in patients with severe hemophilia A without inhibitors
    Allah, M. Nasr
    Pieragostini, R.
    Oka, G.
    Batista, R.
    Stieltjes, N.
    Lopez, I.
    [J]. ANNALES PHARMACEUTIQUES FRANCAISES, 2022, 80 (06): : 915 - 922
  • [26] Emicizumab (Hemlibra) for Subcutaneous Prophylaxis in Hemophilia A
    不详
    [J]. MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2019, 61 (1572): : 77 - 79
  • [27] Peri-operative hemostatic management of tooth extraction in patients with hemophilia A, with and without inhibitors, receiving emicizumab prophylaxis
    Yagyuu, Takahiro
    Furukawa, Shoko
    Zaizen, Miki
    Yata, Sachiko
    Imada, Mitsuhiko
    Nogami, Keiji
    Kirita, Tadaaki
    [J]. HAEMOPHILIA, 2023, 29 (01) : 172 - 179
  • [28] Emicizumab Prophylaxis in Children and Adolescents with Hemophilia A
    Hassan, Tamer
    Zakaria, Marwa
    [J]. INDIAN JOURNAL OF PEDIATRICS, 2024,
  • [29] THE ECONOMIC IMPACT OF REDUCING BLEEDING WITH EMICIZUMAB IN PATIENTS WITH HEMOPHILIA A AND FACTOR VIII INHIBITORS - BRAZILIAN CASE
    Segre, N.
    Mata, V
    Martins, T. D. C.
    [J]. VALUE IN HEALTH, 2022, 25 (12) : S165 - S165
  • [30] Emicizumab prophylaxis in people with hemophilia A and inhibitors: a systematic review and meta-analysis
    Prudente, Tiago Paiva
    Camelo, Ricardo Mesquita
    Guimaraes, Rafael Alves
    Roberti, Maria do Rosario Ferraz
    [J]. SAO PAULO MEDICAL JOURNAL, 2024, 142 (05):
12345